Recommendation of the President – Rubraca (rucaparib)
On 31 January 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 15/2025 on the appraisal Rubraca (rucaparib) under drug program B.50 “Treatment of patients with ovarian cancer, fallopian tube cancer or peritoneal cancer (ICD-10: C56, C57, C48)”